A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

  • STATUS
    Recruiting
  • End date
    May 19, 2025
  • participants needed
    85
  • sponsor
    Nanfang Hospital of Southern Medical University
Updated on 29 June 2021
measurable disease
metastatic adenocarcinoma
irinotecan
cancer chemotherapy
adenocarcinoma
apatinib

Summary

The purpose of this study was to evaluate the overall survival time (OS), objective remission rateORR, progression-free survival timePFS, disease control rateDCRof Carelizumab combined with irinotecan and apatinib for the second-line treatment of locally advanced unresectable, recurrent or metastatic adenocarcinoma of stomach and gastroesophageal junction. At the same time, the safety and tolerance of the scheme were preliminarily evaluated.

Details
Condition gastric cancers, Stomach Cancer, Gastric Cancer, Stomach Discomfort, Gastric Carcinoma, Gastropathy
Treatment Carelizumab Combined With Irinotecan and Apatinib
Clinical Study IdentifierNCT04934618
SponsorNanfang Hospital of Southern Medical University
Last Modified on29 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

The local advanced stage confirmed by histopathology is unresectable, recurrent or metastatic Adenocarcinoma of stomach and gastroesophageal junction
After receiving first-line treatment, the disease progressed or intolerable adverse reactions occurred
At least one measurable lesion or evaluable lesion (according to RECIST 1.1 standard)
Patients agreed to provide blood samples and previously stored tumor tissue samples for tumor microenvironment detection
Age 18 years old and 75 years old
The ECOG score is 0 or 1
The estimated survival time is 3 months
Within 7 days before entering the group, the laboratory test value met the chemotherapy standard
Within 28 days before enrollment, women of childbearing age must confirm that the serum pregnancy test is negative and agree to adopt effective contraceptive measures during the study drug use and within 6 months after the last administration
Patients voluntarily joined the study, signed informed consent, and were able to comply with the visit and related procedures stipulated in the plan

Exclusion Criteria

Participate in other intervention clinical studies at the same time (unless participating in observation studies or being in the follow-up stage of intervention studies), and have received second-line treatment
have received antibody therapy of PD-1, PD-L1, PD-L2, CTLA4, CD137 or any other antibody or drug therapy with t cell co-stimulation or immune checkpoint pathway as specific target
It is known to be allergic to any monoclonal antibody or adjuvant
Received Chinese patent medicines with anti-tumor indications or drugs with immunoregulatory effects (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration
Having undergone major surgery within 4 weeks before the first administration or expecting to undergo surgery during the study treatment
Receive live attenuated vaccine within 4 weeks before the first administration or during the planned study treatment
Received transplantation of solid organs or blood system
Active, known or suspected autoimmune diseases or related medical history in the past 2 years (vitiligo, psoriasis, alopecia or Graves' disease that does not require systematic treatment in the past 2 years, hypothyroidism that only requires thyroid hormone replacement therapy, and type I diabetes patients who only need insulin replacement therapy can enter Group)
Immunosuppressive drugs have been used within 4 weeks before the first administration, excluding local glucocorticoid by nasal spray, inhalation or other routes or systemic glucocorticoid with physiological dose (i.e., prednisone or other glucocorticoid with equivalent dose not exceeding 10mg/ day), or hormone used due to allergy
Known history of primary immunodeficiency disease
Known history of active tuberculosis. 12 known to have a history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive)
after regular antihypertensive treatment, the blood pressure still cannot fall to the normal range (systolic blood pressure > >140mmHg, diastolic blood pressure > >90mmHg)
II grade ii coronary heart disease and arrhythmia (including QTc interval prolongation > >450ms for men and > >470ms for women)
Symptomatic congestive heart failure (new york Heart Association Grade II-IV) or symptomatic or poorly controlled arrhythmia
before the first administration, there was toxicity caused by previous anti-tumor treatment that did not recover to grade 0 or grade 1 of the national cancer institute general adverse event terminology version 4.03 (NCI ctcae version 4.03) (excluding alopecia, fatigue and asymptomatic laboratory abnormalities)
abnormal coagulation function (INR > 1.5 uln, aptt > 1.5 uln), with bleeding tendency
It is known that symptomatic central nervous system metastasis exists. 19. Diagnosed as other malignant tumors within 5 years before the first administration, excluding basal cell carcinoma of skin, squamous cell carcinoma of skin and carcinoma in situ after radical resection
Active infections requiring treatment or systemic anti-infective drugs used within 7 days before the first administration
acute or chronic active hepatitis b: HBV viral load 500 copies /ml 22. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the study
It is known that there are mental diseases or drug abuse situations that may affect the compliance with the test requirements
Acute or chronic active hepatitis C: HCV antibody is positive. 25. Pregnant or lactating women. 26. There are medical histories, diseases, treatments or abnormal laboratory results that may interfere with the test results and prevent the subjects from participating in the study, or the researchers think that participating in the study is not in the best interests of the subjects
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note